i-SENS

아이센스 · 099190

Health Care Medical Devices · KOSDAQ

Small-cap

Market cap US$350.1M (₩483.1B)

Overview

i-SENS makes medical sensors and measuring instruments that let people check their own blood-glucose levels at home, as well as diagnostic equipment used by hospitals at the point of care, meaning tests done on-site rather than sent to a lab.

Its products are used by both individual patients managing diabetes and by healthcare professionals in clinical settings. The company's two core business lines are its consumer blood-glucose monitoring segment and its point-of-care testing segment, listed on KOSDAQ, South Korea's tech-focused smaller-company board.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$228.6M
▲ +8.4% YoY
Operating profit · FY2025
US$5.7M
▲ +196.7% YoY
Net income · FY2025
−US$11.6M
Loss widened

Revenue

  • FY2023US$192.1M
  • FY2024US$211M
  • FY2025US$228.6M

Operating profit

  • FY2023US$7.9M
  • FY2024US$1.9M
  • FY2025US$5.7M

Net income

  • FY2023US$2.5M
  • FY2024−US$1.4M
  • FY2025−US$11.6M

Key ratios (FY2025)

ROE
-4.7%
Debt/Eq
70.7%
Op. margin
2.5%
Net margin
-5.1%
Rev. YoY
▲ +8.4%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.